Clinuvel Pharmaceuticals Limited
CUV.ASXHealth Care
Clinuvel Pharmaceuticals Ltd. is a leading and innovative Australian company focused on the development of SCENESSE (afamelanotide), its proprietary first-in-class drug, as a photoprotective in a range of UV and light related skin disorders a
Market Data
$9.080
+0.0%$451.8M
13.9x
$0.644
0.56%
-0.2%
Latest Earnings
Appendix 4D and Half Year Report
26 February 2026
CLINUVEL reported revenue growth of 4% to $36.9M for the December half-year, driven by continued patient demand for SCENESSE®, particularly in Europe following EMA approval for increased treatments. However, net profit fell 26% to $10.4M due to a 22% increase in expenses related to business expansion, R&D programs, and regulatory costs for NASDAQ ADR uplift. The company maintains a strong balance sheet with $233M in cash reserves and delivered its 10th consecutive half-year profit. Key points: Revenue increased 4% to $36.9M, highest ever December half-year result; Strong cash position of $233M with debt-free status for 21 consecutive years; 10th consecutive half-year profit delivered with 26% net margin
Recent Announcements
CLINUVEL Investor Webinar Half Year Results December 2025
CLINUVEL PHARMACEUTICALS held an investor webinar on 26 February 2026 to present its half-year financial results for the period ended 31 December 2025, with a recording made available on the company's news website.
Half Year Results Presentation
CLINUVEL Pharmaceuticals reported H1 FY2026 results with revenues of A$36.9m (+4% YoY) and profit after tax of A$10.4m (-26% YoY), while maintaining cash reserves of A$233m and debt-free status. The biotech company is progressing its melanocortin pipeline including Phase III vitiligo trials (CUV105 topline results expected H2 2026), NEURACTHEL® for neurological indications, and pursuing a Nasdaq ADR Level II uplisting.
Appendix 4D and Half Year Report
CLINUVEL reported revenue growth of 4% to $36.9M for the December half-year, driven by continued patient demand for SCENESSE®, particularly in Europe following EMA approval for increased treatments. However, net profit fell 26% to $10.4M due to a 22% increase in expenses related to business expansion, R&D programs, and regulatory costs for NASDAQ ADR uplift. The company maintains a strong balance sheet with $233M in cash reserves and delivered its 10th consecutive half-year profit. Key points: Revenue increased 4% to $36.9M, highest ever December half-year result; Strong cash position of $233M with debt-free status for 21 consecutive years; 10th consecutive half-year profit delivered with 26% net margin
Get real-time alerts for CUV
Receive AI-powered earnings summaries and instant notifications when Clinuvel Pharmaceuticals Limited releases results.
Register Free